FDA Approves Date Rape Drug in Treating Sleep Disorder
The Food and Drug Association (FDA) recently approved the dangerous date rape drug GHB for its first legal use as a medical product in treating a complication of narcolepsy, according to the Associated Press. Despite repeated warnings issued by the FDA and others about the use of GHB in date rape, Xyrem, GHB’s brand name, will now be sold under restricted conditions.
The drug first became notorious as a date rape drug in the 1990s – it became popular for its colorless, odorless quality and ability to knock people out. Reports of GHB being slipped into a woman’s drink to render her immobile or unconscious have since multiplied on college campuses across the country. In the March-April 2000 edition of the FDA’s consumer magazine, a 2000 Glamour magazine survey was cited in which 19 percent of female college students said they knew someone who was the victim of the date-rape drug GHB. “The survey helps to confirm GHB's unfortunate standing as a common date-rape drug along with the infamous Rohypnol and others,” the article reads. In addition, the US Drug Enforcement Agency has cited GHB in at least 58 deaths and 5,700 overdoses since 1990.
GHB was originally developed as a surgical anesthetic, but was quickly pulled off the market because of serious side effects such as depressed breathing, coma, and death. In the 1990s, GHB became known as a relatively inexpensive party drug, a performance enhancer for athletes and bodybuilders, and a sex enhancer. GHB is also known as liquid ecstasy, cherry meth, Easy Lay and Georgia homeboy.
Xyrem, distributed by Orphan Medical Inc., will be used to treat cataplexy, a complication of narcolepsy that is characterized by muscle weakness that can, in its most severe forms, cause victims to collapse during waking hours, according to the Associated Press.
Media Resources: Associated Press, 7/18/02; FDA Consumer Magazine March/April 2000
10/31/2014 Federal Judge Exempts Another Catholic University from Birth Control Coverage - A federal judge ruled Tuesday that Ave Maria University, a Catholic university in Florida, does not have to comply with federal rules meant to ensure that covered employees can exercise their right to obtain birth control at no cost.
The Affordable Care Act requires all new health insurance plans to cover all FDA-approved contraceptives - such as the pill, emergency contraceptives, and IUDs - without charging co-pays, deductibles or co-insurance. . . .
10/31/2014 Women of Color in Tennessee Are United in Opposition to Amendment 1 - Just days before the general election in Tennessee, a coalition of community leaders, clergy, and advocates led a press conference encouraging women of color to vote no on Amendment 1, a dangerous and far-reaching measure on the state's ballot.
SisterReach, a grassroots organization focused on "empowering, organizing, and mobilizing women and girls in the community around their reproductive and sexual health to make informed decisions about themselves," organized the press conference "to call attention to the unique concerns Black and poor communities throughout Shelby County and across the state of Tennessee face on a daily basis" and to emphasize how the upcoming election "could further limit [black women's] reproductive, economic, political, and social autonomy."
"We assemble today to impress upon black women and women of color, many of whom are heads of households, to get out and vote," said SisterReacher Founder and CEO Cherisse Scott at the event.
SisterReach has been educating voters about the particularly dangerous impact of Amendment 1 on women of color. . . .
10/30/2014 Medication Abortion Access Threatened by Oklahoma Court Ruling - An Oklahoma state district court judge has refused to block a state law restricting medication abortion, clearing the way for the law to go into affect on November 1.
The Oklahoma Coalition for Reproductive Justice, together with a local abortion clinic in Tulsa, challenged HB 2684 in September, arguing that the law was an unconstitutional restriction on non-surgical abortion in the earliest weeks of pregnancy. . . .